|
Palo Alto, CA - March 25, 2004 — Telik, Inc. (Nasdaq:
TELK) announced TELCYTA™ presentations at the American Association
for Cancer Research 95th annual meeting in Orlando, Florida. The
presentations will report that:
- TELCTYA™ (TLK286) demonstrates synergy, or enhanced growth
inhibition, in combination with paclitaxel, doxorubicin, carboplatin,
cisplatin, docetaxel, gemcitabine and gefitinib in human cancer
cells. Abstract # 2008
- TELCYTA™ (TLK286) is active against paclitaxel resistant
human ovarian cancer cells and also re-sensitizes the cells to
paclitaxel. Abstract # 559
- TELCYTA™ (TLK286) prodrug activation is not affected by
GST P1-1 polymorphisms. Abstract # 3825
TELCYTA™ is a small molecule tumor-activated drug which is
activated by an enzyme present in higher levels in many human cancers
than in normal tissues. Upon activation, an intracellular process
known as apoptosis, or programmed cell death, occurs. A Phase 3
registration trial is in progress with TELCYTA™ in advanced
ovarian cancer (www.assist1-trial.com), and a Phase 3 registration
trial in advanced non-small cell lung cancer (NSCLC) is expected
to be initiated in the near future. TELCYTA™ has been successfully
evaluated in Phase 2 single agent trials in ovarian, NSCLC, breast
and colorectal cancer, and in combination treatment regimens. TELCYTA™
was discovered through the application of Telik’s proprietary
drug discovery technology, TRAP.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize innovative small molecule
drugs to treat serious diseases. Additional information is available
at www.telik.com.
This press release contains “forward-looking” statements.
For this purpose, any statements contained in this press release
that are not statements of historical fact may be deemed to be forward-looking
statements, including any statements regarding the potential for
TELCYTA™ (TLK286) to treat one or more types of cancer. There
are a number of important factors that could cause Telik's results
to differ materially from those indicated by these forward-looking
statements, including, among others, the following: none of Telik’s
product candidates, including TELCYTA™, has been determined
to be safe or effective in humans or received regulatory approval
for marketing; it may take us several years to complete clinical
trials of our product candidates, including TELCYTA™, prior
to seeking regulatory approval for any indication; success in preclinical
testing and early clinical trials does not ensure that later clinical
trials will be successful, and interim results of clinical trials
do not necessarily predict final results; if our competitors develop
and market products that are more effective than our product candidates,
or obtain regulatory approval before we do, our commercial opportunity
will be reduced or eliminated; if we do not obtain regulatory approval
to market products in the United States and foreign countries, we
will not be permitted to commercialize our product candidates; if
we are unable to contract with third parties to manufacture our
product candidates in sufficient quantities and at an acceptable
cost, clinical development of product candidates could be delayed;
and if we are unable to raise adequate funds in the future, we will
not be able to continue to fund our operations and clinical trials
to develop our product candidates. These and other risks are detailed
from time to time in our SEC reports, including our Annual Report
on Form 10-K for the year ended December 31, 2003. Telik does not
undertake any obligation to update forward-looking statements.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
